NCT06898957

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With YL201 With or Without Anti-PD-L1 in Subjects With Extensive Stage Small Cell Lung Cancer

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Amgen · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.

Conditions

• Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	YL201	YL201 will be administered as an IV infusion.
DRUG	Tarlatamab	Tarlatamab will be administered as an IV infusion.
DRUG	Atezolizumab	Atezolizumab will be administered as an IV infusion.
DRUG	Durvalumab	Durvalumab will be administered as an IV infusion.

Timeline

• Start date: 2025-05-16
• Primary completion: 2031-04-23
• Completion: 2031-04-23
• First posted: 2025-03-27
• Last updated: 2026-02-05

Locations

36 sites across 10 countries: United States, Canada, China, France, Germany, Greece, Hungary, Italy, South Korea, Spain

Regulatory

• FDA-regulated drug study